安進公司 AMGN 深 滬
等待開盤 04-02 09:30:00 美东时间
353.28
+1.430
+0.41%
華盛通- 最 高357.00
- 今 開354.90
- 成交量 272.68万股
- 最 低 351.66
- 昨 收 351.85
- 總市值 1904.42亿
- 52周最高 391.29
- 市盈率 靜 24.83
- 換手率 0.51%
- 52周最低 251.77
- 委 比 -97.08%
- 總股本 5.39亿
- 歷史最高 391.29
- 量 比 1.09
- 振 幅 1.52%
- 歷史最低 -28.439
- 每 手 1
- 風險率 34.68%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Trump Administration Prepares 100% Tariffs On Drugmakers Without Pricing Deals: Report
According to a Bloomberg report, Trump may impose 100% tariffs on drugmakers without pricing deals, as part of a broader push to lower drug costs.
今天 16:44
再鼎医药午前涨近5% 与安进公司达成一项全球临床研究合作
再鼎医药（09688）午前涨超4%，截至发稿，股价上涨4.82%，现报15.88港元，成交额2.88亿港元。 4月1日，再鼎医药宣布，与安进公司达成一项全球...
今天 11:37
BUZZ-U.S. STOCKS ON THE MOVE-Cal-Maine, Rivian, Alkermes
BUZZ-U.S. STOCKS ON THE MOVE-Cal-Maine, Rivian, Alkermes Workspace search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 April 1 (Reuters) - Wall Street's main indexes were set for a higher open
04-01 21:14
安进罕见病药物致8人死亡，涉严重肝损伤
（来源：求实药社） 2026年4月1日，美国食品药品监督管理局（FDA）于3月31日发布安全警报，确认安进公司（Amgen）旗下的罕见病药物Tavneos（通用...
04-01 12:02
Rajani Dinavahi, MD, Appointed Chief Medical Officer of Ardelyx
WALTHAM, Mass., April 01, 2026 -- Ardelyx, Inc. announced the appointment of Rajani Dinavahi, MD, as Chief Medical Officer. Dr. Dinavahi brings over two decades of experience in healthcare and biotechnology, with expertise in immuno-oncology, autoimmune diseases, metabolic disease, nephrology, and transplantation. She previously served as Chief Medical Officer at Atara Biotherapeutics. Ardelyx's president and CEO, Mike Raab, highlighted her scien...
04-01 12:01
FDA Warns Of Fatal Liver Risks Linked To Amgen Tavneos Use
FDA flags liver injury risk tied to Amgen Tavneos, citing drug-induced liver injury and rare vanishing bile duct syndrome complications.
04-01 02:05
Merck oral PCSK9 enlicitide shows improved cholesterol lowering vs. non-statins
New phase 3 data found that Merck's oral PCSK9 inhibitor, enlicitide decanoate, led to greater lowering of low-density lipoprotein cholesterol (LDL-C) compared to oral non-statin medicines. The CORALr...
03-31 02:54
Teva gains approval of biosimilar of Amgen's Prolia
The US FDA has approved Teva Pharmaceutical Industries' (TEVA) Ponlimsi (denosumab-adet), a biosimilar to Amgen's (AMGN) osteoporosis drug Prolia (denosumab). Prolia is Amgen's best-selling therapy, b...
03-30 23:01
Neumora Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Neumora Therapeutics宣布，NMRA-511在治疗阿尔茨海默病激惹症的1b期临床试验中展现最佳疗效，正在推进2期临床试验。NMRA-898在精神分裂症治疗中因显著临床效果被选为M4项目领军化合物。KOASTAL-2和-3试验完成入组，预计第二季度公布联合数据。NMRA-215在肥胖症治疗的DIO模型中表现出令人鼓舞的效果，预计2027年第一季度进入临床阶段。公司现金储备1.825亿美元，支持运营至2027年第三季度。
03-30 10:53
Amgen’s Rocatinlimab Trial Completion Signals Next Phase for Atopic Dermatitis Strategy
Amgen Inc ($AMGN) announced an update on their ongoing clinical study. Amgen In...
03-26 00:31
